Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 2/2012

01-02-2012 | Original Article

Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication

Authors: Steffi Wilsky, Katharina Sobotta, Nadine Wiesener, Johanna Pilas, Nadine Althof, Thomas Munder, Peter Wutzler, Andreas Henke

Published in: Archives of Virology | Issue 2/2012

Login to get access

Abstract

Coxsackievirus B3 (CVB3) is a human pathogen that causes acute and chronic infections, but an antiviral drug to treat these diseases has not yet been developed for clinical use. Several intracellular pathways are altered to assist viral transcription, RNA replication, and progeny release. Among these, fatty acid synthase (FAS) expression is increased. In order to test the potential of FAS inhibition as an anti-CVB3 strategy, several experiments were performed, including studies on the correlation of CVB3 replication and FAS expression in human Raji cells and an analysis of the time and dose dependence of the antiviral effect of FAS inhibition due to treatment with amentoflavone. The results demonstrate that CVB3 infection induces an up-regulation of FAS expression already at 1 h postinfection (p.i.). Incubation with increasing concentrations of amentoflavone inhibited CVB3 replication significantly up to 8 h p.i. In addition, suppression of p38 MAP kinase activity by treatment with SB239063 decreased FAS expression as well as viral replication. These data provide evidence that FAS inhibition via amentoflavone administration might present a target for anti-CVB3 therapy.
Appendix
Available only for authorised users
Literature
1.
Gupta S, Markham DW, Drazner MH, Mammen PP (2008) Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 5(11):693–706PubMedCrossRef
2.
Badorff C, Knowlton KU (2004) Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol 193(2–3):121–126PubMedCrossRef
3.
Martin U, Nestler M, Munder T, Zell R, Sigusch HH, Henke A (2004) Characterization of coxsackievirus B3-caused apoptosis under in vitro conditions. Med Microbiol Immunol (Berl) 193(2–3):133–139
4.
Heim A, Weiss S (2004) Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med Microbiol Immunol 193(2–3):149–154PubMedCrossRef
5.
Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R (2004) Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 193(2–3):101–107PubMedCrossRef
6.
Rabenau HF, Richter M, Doerr HW (2010) Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 199(1):45–51PubMedCrossRef
7.
Whitton JL, Cornell CT, Feuer R (2005) Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3(10):765–776PubMedCrossRef
8.
Esfandiarei M, McManus BM (2008) Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3:127–155PubMedCrossRef
9.
Vuorinen T, Vainionpaa R, Heino J, Hyypia T (1999) Enterovirus receptors and virus replication in human leukocytes. J Gen Virol 80(Pt 4):921–927PubMed
10.
Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, Whitton JL (1999) The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 155(4):1205–1215PubMedCrossRef
11.
Vuorinen T, Vainionpaa R, Kettinen H, Hyypia T (1994) Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 84(3):823–829PubMed
12.
Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M (1985) Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 56(2):651–654PubMed
13.
Jarasch N, Martin U, Zell R, Wutzler P, Henke A (2007) Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 12:1633–1643PubMedCrossRef
14.
Klingel K, McManus BM, Kandolf R (1995) Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur Heart J 16(Suppl O):42–45PubMed
15.
Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM (1996) Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 70(7):4632–4645PubMed
16.
Kandolf R, Sauter M, Aepinus C, Schnorr JJ, Selinka HC, Klingel K (1999) Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res 62(2):149–158PubMedCrossRef
17.
Magnani JW, Dec GW (2006) Myocarditis: current trends in diagnosis and treatment. Circulation 113(6):876–890PubMedCrossRef
18.
Henke A, Jarasch N, Wutzler P (2008) Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Rev Vaccines 7(10):1557–1567PubMedCrossRef
19.
Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, McManus BM (2006) Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res 99(4):354–361PubMedCrossRef
20.
Esfandiarei M, Boroomand S, Suarez A, Si X, Rahmani M, McManus B (2007) Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9(10):2358–2371PubMedCrossRef
21.
Feuer R, Mena I, Pagarigan RR, Hassett DE, Whitton JL (2004) Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence/latency. Med Microbiol Immunol 193(2–3):83–90PubMedCrossRef
22.
Rassmann A, Henke A, Zobawa M, Carlsohn M, Saluz HP, Grabley S, Lottspeich F, Munder T (2006) Proteome alterations in human host cells infected with coxsackievirus B3. J Gen Virol 87(Pt 9):2631–2638PubMedCrossRef
23.
Li Y, Webster-Cyriaque J, Tomlinson CC, Yohe M, Kenney S (2004) Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J Virol 78(8):4197–4206PubMedCrossRef
24.
Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28(11):4523–4530PubMedCrossRef
25.
Belov GA, Ehrenfeld E (2007) Involvement of cellular membrane traffic proteins in poliovirus replication. Cell Cycle 6(1):36–38PubMedCrossRef
26.
Kemball CC, Alirezaei M, Flynn CT, Wood MR, Harkins S, Kiosses WB, Whitton JL (2010) Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo. J Virol 84(23):12110–12124PubMedCrossRef
27.
Van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, Galama JM, Melchers WJ (1997) Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J 16(12):3519–3532PubMedCrossRef
28.
Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC (1997) In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 60(9):884–888PubMedCrossRef
29.
Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH, Kern ER (1999) Antiviral activities of biflavonoids. Planta Med 65(2):120–125PubMedCrossRef
30.
Ma SC, But PP, Ooi VE, He YH, Lee SH, Lee SF, Lin RC (2001) Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull 24(3):311–312PubMedCrossRef
31.
Lee JS, Lee MS, Oh WK, Sul JY (2009) Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells. Biol Pharm Bull 32(8):1427–1432PubMedCrossRef
32.
Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S (1996) A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 70(11):7811–7818PubMed
33.
Slifka MK, Pagarigan R, Mena I, Feuer R, Whitton JL (2001) Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 75(5):2377–2387PubMedCrossRef
34.
Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH (2001) Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 39(11):4093–4096PubMedCrossRef
35.
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45PubMedCrossRef
36.
Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A (2010) Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes. Viral Immunol 23(4):369–376PubMedCrossRef
37.
Nissen E, Pauli G, Vollenbroich D (1997) WST-1 assay–a simple colorimetric method for virus titration. In Vitro Cell Dev Biol Anim 33(1):28–29PubMedCrossRef
38.
Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK (2008) WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Methods 73(3):211–215PubMedCrossRef
39.
Dowling S, Cox J, Cenedella RJ (2009) Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 44(6):489–498PubMedCrossRef
40.
Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 20(12):2027–2035PubMedCrossRef
41.
Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL (2002) p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53(2):414–422PubMedCrossRef
42.
King EM, Holden NS, Gong W, Rider CF, Newton R (2009) Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284(39):26803–26815PubMedCrossRef
43.
Rassmann A, Henke A, Jarasch N, Lottspeich F, Saluz HP, Munder T (2007) The human fatty acid synthase: a new therapeutic target for coxsackievirus B3-induced diseases? Antiviral Res 76(2):150–158PubMedCrossRef
44.
45.
Huttunen P, Hyypia T, Vihinen P, Nissinen L, Heino J (1998) Echovirus 1 infection induces both stress- and growth-activated mitogen-activated protein kinase pathways and regulates the transcription of cellular immediate-early genes. Virology 250(1):85–93PubMedCrossRef
46.
Tung WH, Sun CC, Hsieh HL, Wang SW, Horng JT, Yang CM (2007) EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 MAPK, JNK and NF-kappaB in vascular smooth muscle cells. Cell Signal 19(10):2127–2137PubMedCrossRef
47.
Guinea R, Carrasco L (1990) Phospholipid biosynthesis and poliovirus genome replication, two coupled phenomena. EMBO J 9(6):2011–2016PubMed
48.
Fogg MH, Teterina NL, Ehrenfeld E (2003) Membrane requirements for uridylylation of the poliovirus VPg protein and viral RNA synthesis in vitro. J Virol 77(21):11408–11416PubMedCrossRef
49.
Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL (2002) Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76(9):4430–4440PubMedCrossRef
50.
Knowles LM, Axelrod F, Browne CD, Smith JW (2004) A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 279(29):30540–30545PubMedCrossRef
51.
Guerciolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21(Suppl 3):S12–S23PubMed
52.
Ballinger A, Peikin SR (2002) Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 440(2–3):109–117PubMedCrossRef
53.
Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64(6):2070–2075PubMedCrossRef
54.
Adhikari RP, Novick RP (2005) Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion. Microbiology 151(Pt 9):3059–3069PubMedCrossRef
55.
Chayakulkeeree M, Rude TH, Toffaletti DL, Perfect JR (2007) Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. Antimicrob Agents Chemother 51(10):3537–3545PubMedCrossRef
Metadata
Title
Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication
Authors
Steffi Wilsky
Katharina Sobotta
Nadine Wiesener
Johanna Pilas
Nadine Althof
Thomas Munder
Peter Wutzler
Andreas Henke
Publication date
01-02-2012
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 2/2012
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-011-1164-z

Other articles of this Issue 2/2012

Archives of Virology 2/2012 Go to the issue

Brief Report

New Iranian and Australian peach latent mosaic viroid variants and evidence for rapid sequence evolution

Brief Report

Risk factors associated with hepatitis C virus infection in an urban population of the State of Mexico

Original Article

Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus strains

Annotated Sequence Record

A new satellite RNA is associated with natural infections of cucumber mosaic virus in succulent snap bean

Brief Report

Human sapovirus classification based on complete capsid nucleotide sequences

Annotated Sequence Record

Complete sequence of a cryptic virus from hemp (Cannabis sativa)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits